Table 1. Clinical-pathological characteristics of patients comprising the patient-paired TMA.

Patient number	Age	Gender	BRAF mutation status	Ulceration of primary tumor	Location of primary tumor	Location of lymph node metastases	Progression from primary to LN metastases (months)	Location of distant metastases	Progression from LN metastases to distant metastases (months)	Overall survival (months)
1	66	F	WT	Y	Vulva	Inguinal	0	Small bowel	–9.1	35.8
2	70	F	WT	N	Upper back	Axilla	0	Sub-cutaneous	16.5	34
3	83	F	WT	UNK	Leg	Thigh	16	Sub-cutaneous	1.2	37.2
4	34	M	WT	Y	Leg	Inguinal	1	Sub-cutaneous	40.7	99.5
5	59	M	WT	UNK	Conjunctiva	Neck	17.7	Retroperitoneum	14.5	51.1
6	60	M	UNK	UNK	Flank	Axilla	13.4	Supraclavicular LN	0	23.7
7	71	M	WT	UNK	Shoulder	Axilla	0	Muscle	3.9	11.7
8	62	F	UNK	Y	Flank	Axilla	12.2	Sub-cutaneous	–12.17	17.2
9	51	F	UNK	Y	Buttocks	Inguinal	0.63	Sub-cutaneous	3.3	16
10	43	F	WT	Y	Vagina	Inguinal	5.7	Sub-cutaneous	0	24.2
11	85	M	WT	Y	Scalp	Neck	1.9	Salivary gland	10.1	47.2
12	50	F	WT	Y	Vulva	Inguinal	99.4	Lung	–59.9	Alive for 151 months

WT stands for Wild Type; UNK stands for Unknown; LN stands for Lymph Nodes.

F-female, M-male.